Polycystic ovary syndrome (PCOS) is a multidimensional hormonal disorder representing heterogeneous clinical signs. Some of the symptoms include increased androgen production (hyperandrogenism), menstrual disorders, infertility, chronic ovulation, cystic ovaries, menstrual irregularities, a primary defect in the hypothalamic-pituitary axis (abnormal gonadotropin secretions), insulin resistance, and hair loss (
1-
3). The prevalence of PCOS is about 5 - 10% in different populations (
4). Hyperandrogenemia, hyperinsulinemia, insulin resistance, and chronic anovulation are the major heterogeneous characteristics comprising a complex syndrome. Impaired ovarian function in patients with PCOS may cause menstrual disorder as the most common sign (
5).
Hirsutism, acne, hair loss, and infertility can all be found in women with PCOS as the main symptoms of hyperandrogenism. Some possible severe complications in these patients include endometrial and breast cancers, dyslipidemia, hypertension, cardiovascular disease, and diabetes. The prevalence of obesity is about 40% in this group of women. Early diagnosis and treatment can prevent long-term complications, such as type 2 diabetes, cardiovascular disease, and myocardial infarction. However, the main reason for PCOS is unknown yet (
6).
PCOS characteristics entail polycystic ovaries diagnosed on ultrasound and the clinical and biochemical symptoms of hyperandrogenism (
7). Adams et al. stated that PCOS has key diagnostic criteria revealed by transvaginal ultrasound that appears more than ten cysts 2 - 8 mm in diameter arranged around an echo-dense stroma (
8). Takahashi et al. mentioned that ovarian volume higher than 6.2 mm and follicles number equal to or more than 10 (in 2 - 8 mm diameter) are ultrasonic criteria for PCOS diagnosis observed in 94% of PCOS cases (
9).
It is pertinent to mention that some other problems, such as the endocrine syndrome of hyperandrogenism and anovulation, may cause the same ovarian morphology and should be ruled out (
10). Therefore, PCOS is diagnosed based on the clinical and/or biochemical evidence of hyperandrogenism, along with ruling out other reasons for increased androgens, oligo or anovulation, and polycystic ovaries (
11).
Hirsutism is a common disorder that affects 5 - 15% of women of reproductive age and varies based on race and ethnicity (
12-
14). In addition to PCOS, many medications can also cause hirsutism (
15). Approximately, 92% of patients are suffering from this disease based on some studies (
16). In many cases, an increased androgen level or accelerated response of target tissues to androgen is responsible for hirsutism incidence. A high androgen level causes hirsutism in more than 80% of cases (
12,
13).
Elevated LH relative to FSH release has always been noted in PCOS. However, the pulsatile nature of their release and the lack of specificity are the main reasons for not considering LH/FSH ratio as a PCOS diagnostic criteria (
17). Obesity plays an essential role in developing hyperandrogenism, and roughly half of the women with PCOS are obese or overweight (
18,
19). Insulin resistance is found in both obese and non-obese PCOS cases. Hyperinsulinemia has a positive correlation with some degree of hyperandrogenism. However, higher androgen levels and prominent insulin resistance have been reported in women with obesity and PCOS (
19).
Several studies have investigated the various symptoms of PCOS in Iran. However, the relationship between these signs in affected women has not been thoroughly evaluated. Studying simultaneous symptoms and the relationships and interactions between diverse factors can be the basis for the early diagnosis and treatment of this disease.